A 27-year-old patient diagnosed with ADHD returns to the clinic requesting an increase in their Adderall dosage. The patient is currently on the maximum dose of Adderall. As the PMHNP you understand that the medication should not be increased based upon what documented principle?

A. Pharmacological actions of high-dose amphetamine are not linked to therapeutic action in ADHD: Therapeutic effects in ADHD are achieved at moderate doses that optimize dopamine and norepinephrine signaling. Higher doses do not improve attention or hyperactivity control and increase the risk of adverse effects, including cardiovascular events and insomnia. B. The patient is an addict: While stimulant misuse is a concern, the primary reason for not increasing dosage at the maximum is pharmacologic limitations, not presumptive addiction. Careful assessment is necessary, but it is not the documented principle guiding dosage limits. C. Adderall can cause narcolepsy: Adderall is a stimulant and promotes wakefulness; it does not cause narcolepsy. This is not a reason to limit dosage increases in ADHD treatment. D. Adderall can cause neuroleptic malignant syndrome: Neuroleptic malignant syndrome is associated with antipsychotics, not stimulant medications like Adderall. This condition is unrelated to ADHD dose management.